Teva Pharmaceutical Industries valuation

TEVA · NYSE · USD

Compare Teva Pharmaceutical Industries
$42.62Change from previous close: +0.12%Absolute change: +$0.05

Close · November 17, 2026

Valuation

The P/E ratio is 99.0. The average price target of 14 analysts is $50.29.

Data as of November 17, 2026

Teva Pharmaceutical Industries compared with similar companies

Teva Pharmaceutical Industries's P/E (trailing 12 months): 99.0, +176% against the median of a group of 9 similar companies (35.9).

Teva Pharmaceutical Industries's metrics compared with similar companies
MetricTeva Pharmaceutical IndustriesMedian25th–75th percentileBand
P/E (trailing 12 months)99.035.922.2 – 64.5High
Forward P/E13.619.514.1 – 31.2Low
EV/EBITDA14.217.014.2 – 26.0Middle
Price/book6.234.994.42 – 6.39Middle
Price/sales2.884.052.95 – 7.34Low
Gross margin53.5%67.5%64.7% – 77.4%Low
Operating margin19.8%23.4%19.3% – 27.2%Middle
Net margin2.9%16.2%7.8% – 24.5%Low
ROE6.7%12.0%8.0% – 17.8%Low
Debt/equity2.130.500.12 – 2.13Middle

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$49.67B
Enterprise value
$62.59B
PEG
0.71
EV/revenue
3.63

Profitability and growth

ROA
5.4%
Revenue growth (year over year)
-1.9%
Earnings growth (year over year)
-46.0%

Financial health

Total cash
$4.08B
Total debt
$17B
Current ratio
0.95
Quick ratio
0.51

Dividends

Payout ratio
0.0%
Ex-dividend date
November 28, 2017

Analysts and estimates

Average price target
$50.29
Median price target
$49.50
High price target
$57.00
Low price target
$42.12
Analysts with a price target
14
Consensus
Buy
Forward EPS
$3.12
EPS estimate, current year
$2.07

Shares and trading

Beta
0.84
Average volume
6.09M
Shares outstanding
1.17B
Float
1.09B
Institutional ownership
58.9%
Insider ownership
0.6%
Short interest (% of float)
2.4%
Short ratio (days)
4.49